About Cantargia

A Swedish listed biotechnology company

Cantargia is a Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and inflammatory/autoimmune diseases. Cantargia has brought two candidate drugs into clinical development; nadunolimab (CAN04) and CAN10, where the latter was acquired by Otsuka Pharmaceutical in 2025. In addition, the company develops a pre-clinical project CAN14, derived from our antibody platform CANxx. The company is listed on Nasdaq Stockholm’s Main List and traded under the ticker CANTA.

Cantargia AB was founded in 2010 by the researchers Thoas Fioretos, Marcus Järås and Kjell Sjöström with the goal to refine a discovery made by Professor Fioretos and Doctor Järås at Lund University. Their research had shown that leukemic stem cells express a protein on their surface – IL1RAP – that is not expressed to as great a degree on normal stem cells. Further research demonstrated that this protein is also found on cancer cells from numerous solid tumor types.

We develop treatments for life-threatening diseases

Cancer is a very complex disease and despite extensive research there is a great need for new treatments. Cancer continues to be one of the most common causes of death, and a disease that is associated with considerable suffering.

At Cantargia, we consider our work to be not only important and challenging, but also an opportunity to contribute to more effective and safe cancer treatments of the future. We apply our knowledge in the field of cancer research also to the development of products for other severe conditions, such as inflammatory and autoimmune diseases.

Vision

Cantargia’s vision is to develop a new generation of antibody-based treatments aimed at IL1RAP, with the potential to become an important part of future treatments for life-threatening diseases with better efficacy and safety.